Search hospitals

>

Ohio

>

Franklin

Atrium Medical Center-Middletown Regional Hospital

Claim this profile

Franklin, Ohio 45005

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Cancer

Conducts research for Pancreatic Cancer

366 reported clinical trials

4 medical researchers

Photo of Atrium Medical Center-Middletown Regional Hospital in FranklinPhoto of Atrium Medical Center-Middletown Regional Hospital in FranklinPhoto of Atrium Medical Center-Middletown Regional Hospital in Franklin

Summary

Atrium Medical Center-Middletown Regional Hospital is a medical facility located in Franklin, Ohio. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Pancreatic Cancer and other specialties. Atrium Medical Center-Middletown Regional Hospital is involved with conducting 366 clinical trials across 436 conditions. There are 4 research doctors associated with this hospital, such as Howard M. Gross, Tarek M. Sabagh, Michael Guy, MD, and Jhansi L. Koduri.

Area of expertise

1

Breast Cancer

Global Leader

Atrium Medical Center-Middletown Regional Hospital has run 71 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 negative
Stage IV
2

Lung Cancer

Global Leader

Atrium Medical Center-Middletown Regional Hospital has run 56 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at Atrium Medical Center-Middletown Regional Hospital

Lung Cancer

Bladder Cancer

Breast Cancer

Cancer

Esophageal cancer

Breast cancer

Kidney Cancer

Non-Small Cell Lung Cancer

Ovarian Cancer

Cutaneous Melanoma

Image of trial facility.

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Atrium Medical Center-Middletown Regional Hospital?

Where is Atrium Medical Center-Middletown Regional Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does Atrium Medical Center-Middletown Regional Hospital accept?

What awards or recognition has Atrium Medical Center-Middletown Regional Hospital received?